Capricorn Therapeutics (CAPR) shares skyrocketed after successful late-stage HOPE-3 trial results for Duchenne Muscular Dystrophy treatment, deramiocel, causing notable short-seller Martin Shkreli to reverse his bearish stance. Wall Street firms recommend owning CAPR shares, with analysts raising price targets post-trial. Alliance Global Partners predicts a potential 60% upside to $48 by 2026. However, caution is advised due to speculative surge and regulatory uncertainties, emphasizing the importance of evaluating risk-appetite before investing in CAPR.

Read more at Yahoo Finance: This ‘Strong Buy’ Penny Stock Just More Than Quadrupled on Clinical Trial Results. Should You Buy It Here?